Epidemiology of anaphylaxis: is the trend still going up?
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
medline:
31
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
ppublish
Résumé
To understand the current global scale of anaphylaxis and identify possible strategies to increase the accuracy of epidemiological data. Anaphylaxis mortality and morbidity statistics may gain new perspectives with the global implementation of the ICD-11. Improving the quality of epidemiological data related to anaphylaxis should clarify some areas of uncertainty about risk factors, leading to better targeting of strategies to protect those patients at risk, and support decision-making to facilitate health care planning and implementation of public health measures to prevent anaphylaxis. The true rate of anaphylaxis is unknown due to a number of factors, such as misdiagnosis, miscoding and undernotification. Moreover, there is lack of information about anaphylaxis epidemiology in many countries. Difficulties on collecting accurate and comparable data should be acknowledged and anaphylaxis data can vary widely. Currently, most robust data are derived from hospitalization datasets and national mortality databases. Anaphylaxis accounts for up to 0.26% of overall hospital admissions. It is suggested that the number of hospital admissions for anaphylaxis is increasing in many countries, both with respect to all-causes of anaphylaxis and by trigger, but the mortality rate remains low. However, there are still great challenges in capturing quality anaphylaxis mortality and morbidity statistics. Better understanding of anaphylaxis trends should clarify some areas of uncertainty about risk factors and prospect effective prevention strategies. As the knowledge derived from populations is key information for more realistic decision-making, the construction of the new section addressed to anaphylaxis in the ICD-11 will allow the collection of more accurate epidemiological data to support high quality management of patients, and to better facilitate health care planning to implement public health measures, reduce the morbidity and mortality attributable to anaphylaxis.
Identifiants
pubmed: 37548324
doi: 10.1097/ACI.0000000000000933
pii: 00130832-990000000-00082
doi:
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
349-356Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
World Health Organization website. Available at: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases (accessed October 2020).
World Health Organization website. Available at: https://www.who.int/nmh/events/ncd_action_plan/en/ (accessed May 2023).
Papadopoulos NG, et al. Research needs in allergy: an EAACI position paper, in collaboration with EFA. Clin Transl Allergy 2012; 2:21.
Pawankar R, et al. The WAO white book on allergy. Update 2013. Available at: https://www.worldallergy.org/wao-white-book-on-allergy (accessed October 2020).
Simons FER, Ardusso LR, Bilò MB, et al. International consensus on (ICON) anaphylaxis. World Allergy Organ J 2014; 7:9.
Epidemiology is a science of high importance. Nat Commun 2018;9:1703. Available at: https://doi.org/10.1038/s41467-018-04243-3 .
World Health Organization website. Available at: https://www.who.int/topics/epidemiology/en/ (accessed December 2018).
The Centers for Disease Control website. Available at: https://www.cdc.gov/about/history/index.html (accessed December 2018).
Hernandez JBR, Kim PY. Epidemiology morbidity and mortality. 2020. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020. PMID: 31613448.
Tanno LK, Bierrenbach AL, Simons FER, et al. Critical view of anaphylaxis epidemiology: open questions and new perspectives. Allergy Asthma Clin Immunol 2018; 14:12.
Tanno LK, Calderon MA, Goldberg BJ, et al. Constructing a classification of hypersensitivity/allergic diseases for ICD-11 by crowdsourcing the allergist community. Allergy 2015; 70:609–615.
Tanno LK, Simons FER, Sanchez-Borges M, et al. Joint Allergy Academies. Applying prevention concepts to anaphylaxis: a call for worldwide availability of adrenaline auto-injectors. Clin Exp Allergy 2017; 47 (9):1108–1114.
Tanno LK, Demoly P. Joint Allergy AcademiesAction plan to ensure global availability of adrenaline autoinjectors. J Investig Allergol Clin Immunol 2020; 30:77–85.
Panesar SS, Javad S, de Silva D, et al. on behalf of the EAACI Food Allergy and Anaphylaxis Group. The epidemiology of anaphylaxis in Europe: a systematic review. Allergy 2013; 68:1353–1361.
Neugut AI, Ghatak AT, Miller RL. Anaphylaxis in United States: an investigation into its epidemiology. Arch Intern Med 2001; 161:15–21.
Asai Y, Yanishevsky Y, Clarke A, et al. Rate, triggers, severity and management of anaphylaxis in adults treated in a Canadian emergency department. Int Arch Allergy Immunol 2014; 164:246–252.
Turner PJ, Campbell DE, Motouse MS, Campbell RL. Global trends in anaphylaxis epidemiology and clinical implications. J Allergy Clin Immunol Pract 2020; 8:1169–1176.
Tejedor Alonso MA, Moro Moro M, Múgica García MV. Epidemiology of anaphylaxis. Clin Exp Allergy 2015; 45:1027–1039.
Mullins RJ, Dear KB, Tang ML. Time trends in Australian hospital anaphylaxis admissions in 1998–1999 to 2011–2012. J Allergy Clin Immunol 2015; 136:367–375.
Tejedor-Alonso MA, Moro-Moro M, Mosquera Gonzalez M, et al. Increased incidence of admissions for anaphylaxis in Spain 1998–2011. Allergy 2015; 70:880–883.
Yao TC, Wu AC, Huang YW, et al. Increasing trends of anaphylaxis-related events: an analysis of anaphylaxis using nationwide data in Taiwan, 2001–2013. World Allergy Organ J 2018; 11:23.
Motosue MS, Bellolio MF, Van Houten HK, et al. Outcomes of emergency department anaphylaxis visits from 2005 to 2014. J Allergy Clin Immunol Pract 2018; 6:1002–1009. e2.
Turner PJ, Worm M, Ansotegui IJ, et al. WAO Anaphylaxis Committee. Time to revisit the definition and clinical criteria for anaphylaxis? World Allergy Organ J 2019; 12 (10):100066.
Dhopeshwarkar N, Sheikh A, Doan R, et al. Drug-induced anaphylaxis documented in electronic health records. J Allergy Clin Immunol Pract 2019; 7:103–111.
Pagani S, Lombardi N, Crescioli G, et al. On Behalf Of The MEREAFaPS Study Group. Drug-related hypersensitivity reactions leading to emergency department: original data and systematic review. J Clin Med 2022; 11:2811.
Cardoso B, Moscoso T, Morais-Almeida M, et al. Economic burden of drug-induced anaphylaxis: what can we do better? Curr Opin Allergy Clin Immunol 2022; 22:234–241.
Jares EJ, Cardona V, Gómez RM, et al. Latin American anaphylaxis registry. World Allergy Organ J 2023; 16:100748.
Andrade S, Bartels DB, Lange R, et al. Safety of metamizole: a systematic review of the literature. J Clin Pharm Ther 2016; 41:459–477.
Florvaag E, Johansson S. The pholcodine Case. Cough medicines, IgE-sensitization, and anaphylaxis: a devious connection. World Allergy Organ J 2012; 5:73–78.
Tanno LK, Demoly P. Anaphylaxis in children. Pediatric Allergy and Immunol 2020; 26:8–10.
Yu RJ, Krantz MS, Phillips EJ, Stone CA Jr. Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS). J Allergy Clin Immunol Pract 2021; 9:819–829. e2.
Carra S, Schatz M, Mertes PM, et al. Anaphylaxis and pregnancy: a systematic review and call for public health actions. J Allergy Clin Immunol Pract 2021; 9:4270–4278.
Mullins RJ, Wainstein BK, Barnes EH, et al. Increases in anaphylaxis fatalities in Australia from 1997 to 2013. Clin Exp Allergy 2016; 46:1099–1110.
Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis in the United States, 1999–2010: temporal patterns and demographic associations. J Allergy Clin Immunol 2014; 134:1318–1328. e7.
Tanno LK, Gauthier A, Allichon S, Demoly P. Global patterns of drug allergy-induced fatalities: a wake-up call to prevent avoidable deaths. Curr Opin Allergy Clin Immunol 2022; 22:215–220.
Gupta RS, Warren CM, Smith BM, et al. The public health impact of parent-reported childhood food allergies in the United States. Pediatrics 2018; 142:e20181235.
Nwaru BI, Hickstein L, Panesar SS, et al. The epidemiology of food allergy in Europe: a systematic review and meta-analysis. Allergy 2014; 69:62–75.
Pouessel G, Turner PJ, Worm M, et al. Food-induced fatal anaphylaxis: From epidemiological data to general prevention strategies. Clin Exp Allergy 2018; 48 (12):1584–1593.
Prescott SL, Pawankar R, Allen KJ, et al. A global survey of changing patterns of food allergy burden in children. World Allergy Organ J 2013; 6 (1):21.
Skolnick HS, Conover-Walker MK, Koerner CB, et al. The natural history of peanut allergy. J Allergy Clin Immunol 2001; 107:367–374.
Dölle-Bierke S, Höfer V, Francuzik W, et al. Food-Induced Anaphylaxis: Data From the European Anaphylaxis Registry. J Allergy Clin Immunol Pract 2023; 11:2069.e7–2079.e7.
Roberts G, Vazquez-Ortiz M, Knibb R, et al. EAACI Guidelines on the effective transition of adolescents and young adults with allergy and asthma. Allergy 2020; 75:2734–2752.
Bilò MB, Pravettoni V, Bignardi D, et al. Hymenoptera venom allergy: management of children and adults in clinical practice. J Investig Allergol Clin Immunol 2019; 29:180–205.
Bilò MB, Bonifazi F. The natural history and epidemiology of insect venom allergy: clinical implications. Clin Exp Allergy oct 2009; 39:1467–1476.
Potiwat R, Sitcharungsi R. Ant allergens and hypersensitivity reactions in response to ant stings. Asian Pac J Allergy Immunol 2015; 33:267–275.
Pouessel G, Jean-Bart C, Deschildre A, et al. Food-induced anaphylaxis in infancy compared to preschool age: a retrospective analysis. Clin Exp Allergy 2020; 50:74–81.
Worm M, Moneret-Vautrin A, Scherer K, et al. First European data from the network of severe allergic reactions (NORA). Allergy 2014; 69:1397–1404.
Tanno LK, Demoly P. Epidemiology of anaphylaxis. Curr Opin Allergy Clin Immunol 2021; 21 (2):168–174.
World Health Organization, ICD-11 Beta Draft website. Available at: http://apps.who.int/classifications/icd11/browse/l-m/en (accessed June 2023).
Tanno LK, Calderon MA, Goldberg BJ, et al. Categorization of allergic disorders in the new World Health Organization International Classification of Diseases. Clin Transl Allergy 2014; 4:42.
Tanno LK, Ganem F, Demoly P, et al. Undernotification of anaphylaxis deaths in Brazil due to difficult coding under the ICD-10. Allergy 2012; 67:783–789.
Tanno LK, Molinari N, Bruel S, et al. Joint Allergy Academies. Field-testing the new anaphylaxis’ classification for the WHO International Classification of Diseases-11 revision. Allergy 2017; 72:820–826.
Tanno LK, Simons FER, Annesi-Maesano I, et al. Fatal anaphylaxis registries data support changes in the WHO Anaphylaxis Mortality Coding Rules. Orphanet Orphanet J Rare Dis 2017; 12:8.
Tanno LK, Calderon MA, Demoly P. on behalf the Joint Allergy Academies. New allergic and hypersensitivity conditions section in the International Classification of Diseases-11. Allergy Asthma Immunol Res 2016; 8:383–388.
Demoly P, Tanno LK, Akdis CA, et al. Global classification and coding of hypersensitivity diseases - an EAACI - WAO survey, strategic paper and review. Allergy 2014; 69:559–570.
Tanno LK, Calderon M, Papadopoulos NG, Demoly P. Mapping hypersensitivity/allergic diseases in the International Classification of Diseases (ICD)-11: cross-linking terms and unmet needs. Clin Transl Allergy 2015; 5:20.
Tanno LK, Calderon MA, Demoly P. on behalf the Joint Allergy Academies. Making allergic and hypersensitivity conditions visible in the International Classification of Diseases-11. Asian Pac Allergy 2015; 5:193–196.
Tanno LK, Calderon MA, Demoly P. on behalf the Joint Allergy Academies. Optimization and simplification of the allergic and hypersensitivity conditions classification for the ICD-11. Allergy 2016; 71:671–676.
Tanno LK, Calderon MA, Papadopoulos NG, et al. Joint Allergy Academies. Surveying the new allergic and hypersensitivity conditions chapter of the International classification of diseases (ICD)-11. Allergy 2016; 71:1235–1240.
Tanno LK, Calderon M, Demoly P. Joint Allergy Academies. Supporting the validation of the new allergic and hypersensitivity conditions section of the World Health Organization International Classification of Diseases-11. Asia Pac Allergy 2016; 6:149–156.
Tanno LK, Calderon M, Sublett JL, et al. Joint Allergy Academies. Smoothing the transition from International Classification of Diseases, Tenth Revision, Clinical Modification to International Classification of Diseases, Eleventh Revision. J Allergy Clin Immunol Pract 2016; 4:1265–1267.
Tanno LK, Bierrenbach AL, Calderon MA, et al. Joint Allergy Academies. Decreasing the undernotification of anaphylaxis deaths in Brazil through the International Classification of Diseases (ICD)-11 revision. Allergy 2017; 72:120–125.
Tanno LK, Ansotegui I, Demoly P. Globalization and anaphylaxis. Curr Opin Allergy Clin Immunol 2018; 18:365–369.
Tanno LK, Casale T, Papadopoulos NG, et al. A call to arms of specialty societies to review the WHO International Classification of Diseases, Eleventh Revision terms appropriate for the diseases they manage: the example of the Joint Allergy Academies. Allergy Asthma Proc 2017; 38 (4):54–55.
Tanno LK, Chalmers R, Bierrenbach AL, et al. on behalf Joint Allergy Academies. Changing the history of anaphylaxis mortality statistics through the World Health Organization's International Classification of Diseases (ICD)-11. J Allergy Clin Immunol 2019; 144:627–633.
WHO website, WHO Collaborating Centres. Available at: http://apps.who.int/whocc/Detail.aspx?cc_ref=FRA-133&designation_date1=1/6/2018&designation_date2=18/7/2018& (accessed January 2019).
Juhn Y, Liu H. Artificial intelligence approaches using natural language processing to advance HER-based clinical research. J Allergy Clin Immunol 2020; 145:463–469.